MaxCyte is a commercial cell engineering company engaged on providing enabling platform technologies to improve cell-based research and development as well as cell therapeutic discovery, development and commercialization. Co.'s ExPERT platform, which is based on its Flow Electroporation technology, has been designed to address this cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes: three instruments, which Co. calls the ATx, STx and GTx. We show 12 historical shares outstanding datapoints in our MXCT shares outstanding history coverage, used to compute MXCT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MXCT market cap history over the course of time is important for investors
interested in comparing MXCT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MXCT versus a peer is one thing; comparing
MXCT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MXCT can fluctuate over the course of history.
With this page we aim to empower investors researching MXCT by allowing them to research the MXCT market cap history. |
Free MXCT Email Alerts:
Video: The Importance of Market Cap
